Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 267 entries
View as:

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02711137 Org: User:
Start: 05/18/16 End: 02/13/19 Due: 02/13/20

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03656536 Org: User:
Start: 06/03/19 End: 07/27/28 Due: 07/27/29

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Phase: N/A Priority: Normal
NCT ID: NCT01340651 Org: User:
Start: 03/31/11 End: 07/31/12 Due: 07/31/13

realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Phase: N/A Priority: Normal
NCT ID: NCT04981795 Org: User:
Start: 09/20/21 End: 08/31/26 Due: 08/31/27

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

Phase: N/A Priority: Normal
NCT ID: NCT05624723 Org: User:
Start: 01/12/23 End: 02/07/24 Due: 02/07/25

Efficacy and Safety of Pemigatinib in Participants With Solid Tumors With FGFR Mutations or Translocations (FIGHT-208)

Phase: N/A Priority: Normal
NCT ID: NCT04003623 Org: User:
Start: 10/31/19 End: 06/12/20 Due: 06/12/21

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

Phase: N/A Priority: Normal
NCT ID: NCT04831996 Org: User:
Start: 05/04/21 End: 07/08/22 Due: 07/08/23

A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT03514407 Org: User:
Start: 06/27/18 End: 06/25/20 Due: 06/25/21

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Phase: N/A Priority: Normal
NCT ID: NCT04629508 Org: User:
Start: 07/12/21 End: 08/24/23 Due: 08/24/24

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Phase: N/A Priority: Normal
NCT ID: NCT03822117 Org: User:
Start: 10/17/19 End: 03/29/22 Due: 03/29/23

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Phase: N/A Priority: Normal
NCT ID: NCT02018861 Org: User:
Start: 09/22/16 End: 04/12/21 Due: 04/12/22

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase: N/A Priority: Normal
NCT ID: NCT03112603 Org: User:
Start: 06/29/17 End: 12/15/22 Due: 12/15/23

A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06505265 Org: User:
Start: 08/12/24 End: 09/18/24 Due: 09/18/25

A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris

Phase: N/A Priority: Normal
NCT ID: NCT03780166 Org: User:
Start: 03/31/19 End: 11/30/20 Due: 11/30/21

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

Phase: N/A Priority: Normal
NCT ID: NCT04530344 Org: User:
Start: 09/24/20 End: 11/14/22 Due: 11/14/23

A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)

Phase: N/A Priority: Normal
NCT ID: NCT03314922 Org: User:
Start: 08/02/18 End: 03/09/23 Due: 03/09/24

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Phase: N/A Priority: Normal
NCT ID: NCT04476043 Org: User:
Start: 08/25/20 End: 08/16/23 Due: 08/16/24

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT03132324 Org: User:
Start: 04/20/17 End: 10/03/18 Due: 10/03/19

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03374488 Org: User:
Start: 12/22/17 End: 07/23/20 Due: 07/23/21

A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

Phase: N/A Priority: Normal
NCT ID: NCT06310304 Org: User:
Start: 03/26/24 End: 05/15/24 Due: 05/15/25

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02257619 Org: User:
Start: 09/30/14 End: 04/30/16 Due: 04/30/17

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

Phase: N/A Priority: Normal
NCT ID: NCT06039384 Org: User:
Start: 12/28/23 End: 11/03/25 Due: 11/03/26

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Phase: N/A Priority: Normal
NCT ID: NCT02178722 Org: User:
Start: 07/17/14 End: 11/06/20 Due: 11/06/21

A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib

Phase: N/A Priority: Normal
NCT ID: NCT04640025 Org: User:
Start: 03/10/21 End: 06/22/26 Due: 06/22/27

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Phase: N/A Priority: Normal
NCT ID: NCT02953678 Org: User:
Start: 12/30/16 End: 08/14/19 Due: 08/14/20